MEDU-02. DIFFERENTIAL EXPRESSION OF FOLATE RECEPTOR 1 IN MEDULLOBLASTOMA AND ITS RELATIONSHIP TO CLINICOPATHOLOGICAL CHARACTERISTICS AND TARGETED THERAPY

Hailong Liu,Chunjiang Yu,Qianwen Sun,Yongmei Song,Youliang Sun,Yongqiang Liu,Yuduo Guo,Weihai Ning,Yanming Qu,Hongyu Yuan
DOI: https://doi.org/10.1093/neuonc/nox083.153
2017-01-01
Neuro-Oncology
Abstract:Medulloblastoma is the most common malignant CNS tumor of childhood. High expression of folate receptor 1 (Folr1) was observed in some malignant epithelial tumors. However its expression and the role for clinicopathological significance and targeted therapeutic potential in MB still remain unclear. Currently we have detected the expression of Folr1 in MB and identified its clinical, pathological and radiological values to be considered as a biomarker for diagnosis of MB. Then we studied the targeted treatment of MB with Folr1 targeted cytarabine (Folr1-Ara-C) both in vitro and in vivo. Folr1 were overexpressed in MB, while the level correlated with pathological subtypes. Folr1 expression was positively correlated with CSF spreading, Ki-67, MMP9, pathological subtypes and serum Folr1. Factors of age, CSF spreading, Ki-67, MMP9, strong Folr1 expression and pathological subtypes were found to be the independent prognostic values for patients with MB. Serum Folr1 showed rational sensitivity and specificity in demonstrating histological types. Folr1-Ara-C led to changes in cellular proliferation and invasion with down-regulation of MMPs proteins and activation of apoptosis in vitro. Using mouse xenografts, Folr1-Ara-C suppressed tumor growth and improved survival by MRI and PET/CT. Immunohistochemical analysis showed decreased Ki-67 and MMP9 index suggesting the effects on proliferation and invasion in vivo. Folr1 may be considered as a predictive candidate for histological types and serum Folr1 may be a novel non-invasive biomarker. The application of Folr1-Ara-C contributed to be one kind of targeted therapies for MB.
What problem does this paper attempt to address?